Announcements
- MediWound to Present New Data from EscharEx® Phase II Studies at Three Leading Wound Care Conferences
- MediWound Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
- MediWound to Report Fourth Quarter and Full Year 2023 Financial Results
- MediWound Announces Positive Results in Head-to-Head Comparison of EscharEx® vs. SANTYL® within the ChronEx Phase II Randomized Controlled Study
- MediWound to Participate in Two Upcoming Investor Conferences
- MediWound Announces that FDA has Accepted for Review the Supplement to the NexoBrid BLA to Include Pediatric Patients with Severe Thermal Burns
- MediWound Secures Additional U.S. Department of Defense Funding to Advance NexoBrid® Development for the U.S. Army
- MediWound Announces Peer-Reviewed Publication of EscharEx® Mechanism of Action Study Assessing Its Effects on Biofilm and Microbial Loads
- MediWound Reports Third Quarter 2023 Financial Results and Provides Company Update
- MediWound Announces Appointment of Shmulik Hess, Ph.D. as Chief Operating Officer and Chief Commercial Officer
More ▼
Key statistics
As of last trade Mediwound Ltd (M8W:FRA) traded at 16.70, -10.70% below its 52-week high of 18.70, set on Apr 17, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 16.20 |
---|---|
High | 16.70 |
Low | 16.20 |
Bid | 17.00 |
Offer | 17.50 |
Previous close | 16.20 |
Average volume | 338.89 |
---|---|
Shares outstanding | 9.49m |
Free float | 7.05m |
P/E (TTM) | -- |
Market cap | 167.62m USD |
EPS (TTM) | -0.768 USD |
Data delayed at least 15 minutes, as of Apr 26 2024 07:40 BST.
More ▼